1 results match your criteria: "Spanish National Health Center Carlos iii[Affiliation]"
The Potential of Metabolomics to Find Proper Biomarkers for Addressing the Neuroprotective Efficacy of Drugs Aimed at Delaying Parkinson's and Alzheimer's Disease Progression.
Cells
July 2024
Network Center Neurodegenerative Diseases, CiberNed, Spanish National Health Center Carlos iii, Monforte de Lemos 3, 28029 Madrid, Spain.
Article Synopsis
- The text discusses the need for better tools to measure neuroprotection in Alzheimer's and Parkinson's diseases, emphasizing that current methods lack specific markers.
- It outlines the main outcome measures used in clinical trials for these neurodegenerative diseases since 2018, noting that they do not specifically assess neuroprotection.
- Finally, the text highlights the potential of metabolomics, utilizing body fluids to discover new biomarkers related to neuroprotection, thanks to recent advancements in technology that allow for better detection of relevant metabolites.